Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 12, Décembre 2015
Page(s) 1109 - 1114
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153112014
Publié en ligne 16 décembre 2015
  1. Joffres M, Shields M, Tremblay MS. Connor Gorber S. Dyslipidemia prevalence, treatment, control and awareness in the Canadian health measures survey. Can J Public Health 2013 ; 104 : 252–257.
  2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005 ; 366 : 1267–1278. [CrossRef] [PubMed]
  3. Macedo AF, Taylor FC, Casas JP, et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014 ; 12 : 51. [CrossRef] [PubMed]
  4. Maki KC, Ridker PM, Brown WV, et al. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol 2014 ; 8 : 17–29. [CrossRef]
  5. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013 ; 29 : 1553–1568. [CrossRef] [PubMed]
  6. Mansi I, Frei CR, Pugh MJ, et al. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med 2013 ; 173 : 1318–1326. [CrossRef] [PubMed]
  7. Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014 ; 8 (suppl 3) : S8–71. [CrossRef]
  8. Thompson PD, Parker B. Statins, exercise, and exercise training. J Am Coll Cardiol 2013 ; 62 : 715–716. [CrossRef] [PubMed]
  9. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013 ; 127 : 96–103. [CrossRef] [PubMed]
  10. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014 ; 168 : 6–15. [CrossRef] [PubMed]
  11. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014 ; 21 : 464–474. [CrossRef] [PubMed]
  12. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther 2005 ; 19 : 403–414. [CrossRef] [PubMed]
  13. Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther 2010 ; 90 : 1530–1542. [CrossRef] [PubMed]
  14. Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004 ; 57 : 525–528. [CrossRef] [PubMed]
  15. Riechmann SE, Andrews RD, MacLean DA, Sheather S. Statins and dietary and serum cholesterol are associated with increased lean mass following resistance training. J Gerontol Biol Sci Med Sci 2007 ; 62 : 1164–1171. [CrossRef]
  16. Panayiotou G, Paschalis V, Nikolaidis MG, et al. No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study. Scand J Med Sci Sports 2013 ; 23 : 556–567. [PubMed]
  17. Murlastis Z, Radak Z. The effects of statin medications on aerobic exercise capacity and training tdaptations. Sports Med 2014 ; 44 : 1519–1530. [CrossRef] [PubMed]
  18. Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010 ; 42 : 469–479. [CrossRef]
  19. Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013 ; 62 : 709–714. [CrossRef] [PubMed]
  20. Rengo JL, Savage PD, Toth MJ, Ades PA. Statin therapy does not attenuate exercise training response in cardiac rehabilitation. J Am Coll Cardiol 2014 ; 63 : 2050–2055. [CrossRef] [PubMed]
  21. Morandi A, Girard TD, Shintani A, et al. Association between statin use at admission to inpatient rehabilitation and functional status at discharge among older patients. Rejuvenation Res 2014 ; 17 : 490–495. [CrossRef] [PubMed]
  22. Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care 2013 ; 36 : 325–330. [CrossRef]
  23. Taha DA, De Moor CH, Barrett DA, Gershkovich P. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Transl Res 2014 ; 164 : 85–109. [CrossRef]
  24. Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse affects. Br J Clin Pharmacol 2014 ; 78 : 454–466. [CrossRef] [PubMed]
  25. Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun 2014 ; 5 : 5068. [CrossRef] [PubMed]
  26. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014 ; 63 : 2935–2959. [CrossRef] [PubMed]
  27. DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 2013 ; 6 : 400–408. [CrossRef] [PubMed]
  28. Search Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008 ; 359 : 789–799. [CrossRef] [PubMed]
  29. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014 ; 24 : 4–15. [CrossRef] [PubMed]
  30. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013 ; 368 : 1279–1290. [CrossRef] [PubMed]
  31. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy - European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Hearth J 2015 ; 36 : 1012–1022. [CrossRef]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.